Showing results (101-110 of 154) with videos related to
Sort By:
Pageof 16
Nature|February 21, 2012
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeSevin Turcan, Daniel Rohle, Anuj Goenka, et al.Cancer Discovery|September 12, 2015
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK InhibitionMaria E R Garcia-Rendueles, Julio C Ricarte-Filho, Brian R Untch, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2018
Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular CarcinomaJu Youn Lee, Michail Schizas, Felipe C Geyer, et al.Nature Genetics|May 6, 2014
A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutationsShinji Kohsaka, Neerav Shukla, Nabahet Ameur, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2014
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyMartin H Voss, A Ari Hakimi, Can G Pham, et al.Proceedings of the National Academy of Sciences of the United States of America|December 21, 2007
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibJames Bean, Cameron Brennan, Jin-Yuan Shih, et al.Nucleic Acids Research|April 20, 2021
Measuring nonhomologous end-joining, homologous recombination and alternative end-joining simultaneously at an endogenous locus in any transfectable human cellSuleman S Hussain, Rahul Majumdar, Grace M Moore, et al.Genome Biology|August 29, 2014
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesionsA Rose Brannon, Efsevia Vakiani, Brooke E Sylvester, et al.Blood|December 21, 2018
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphomaChristian Grommes, Sarah S Tang, Julia Wolfe, et al.Nature Genetics|August 30, 2011
Germline mutations in BAP1 predispose to melanocytic tumorsThomas Wiesner, Anna C Obenauf, Rajmohan Murali, et al.Pageof 16